<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pathology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98ADFA11-C4BA-4B89-8C2F-85738409A6B4"><gtr:id>98ADFA11-C4BA-4B89-8C2F-85738409A6B4</gtr:id><gtr:firstName>Helga</gtr:firstName><gtr:surname>Schneider</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE015395%2F1"><gtr:id>E086C2C8-583F-4AB1-9B6E-6F9C22D85D97</gtr:id><gtr:title>Trim modulation of CTLA-expression and function</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E015395/1</gtr:grantReference><gtr:abstractText>The immune system provides protection from opportunistic bacterial and viral infections. The regulation of T-cell activation is a critical step in the immune response. CD28 and CTLA-4 are cell surface molecules which play central roles in the regulation of T-cell function. While CD28 augments T-cell responses, CTLA-4 generates potent signals that dampen the immune response. The importance of CTLA-4 is demonstrated in mice lacking this receptor. They develop a massive lymphoproliferative disorder and die at an early age. In contrast to CD28, most of CTLA-4 is localized inside the cell. This application proposes to investigate how CTLA-4 is transported to the cell surface and controls T-cell responses.</gtr:abstractText><gtr:technicalSummary>CD28 and CTLA-4 determine the ultimate outcome of the immune response following ligation of theTcR/CD3 complex. Both bind to CD80 and CD86 and are required for optimal T-cell activation. In contrast to CD28, which enhances and sustains T-cell responses, CTLA-4 potently inhibits T-cell activation. CTLA-4 deficient mice show an autoimmune phenotype with organ destruction. One of the unusual characteristics of CTLA-4 is the fact that it is primarily located in intracellular compartments. Little of the co-receptor can be detected on the surface of cells, even during its optimal expression following T-cell activation. Given the importance of CTLA-4 to T-cell immunity, a major outstanding question concerns the mechanism by which the co-receptor is shuttled to the cell surface to down-regulate the immune response. Our previous findings showed that TRIM (T-cell receptor interacting molecule) facilitates shuttling of CTLA-4 from the trans Golgi network (TGN) to the surface of T-cells. The adaptor was found to bind and co-localize with CTLA-4 in the TGN. TRIM over-expression increased CTLA-4 expression and its ability to inhibit T-cell proliferation and IL-2 production. The aim of this proposal is to better define the mechanisms and pathways utilized by the TRIM/CTLA-4 complex in regulating T-cell function.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299322</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>CTLA-4 potently inhibits T-cell activation, and yet primarily resides in intracellular compartments. We previously showed that the transmembrane adapter TRIM associates and facilitates the transport of CTLA-4 to the cell surface. This finding identified a novel function of transmembrane adapter proteins (TRAPs), and raised the question whether other related non-raft adapters play a similar role. We identified another adapter termed LAX which binds, co-localizes and facilitates CTLA-4 transport to the cell surface through binding to Rab8, a member of the Rab GTPase superfamily that coordinate intracellular trafficking. Disruption of LAX/Rab8 binding or reduction of LAX or Rab8 expression by small hairpin RNAs resulted in reduced CTLA-4 surface expression. Our findings on LAX suggest that CTLA-4 and possibly other receptors are transported by TRAPs to the cell surface.</gtr:description><gtr:exploitationPathways>Optimal regulation of surface expression of the inhibitory receptor CTLA-4 is crucial for the balance of stimulatory and inhibitory signals to elicit proper immune responses. Minor changes in surface expression levels could have major effects on the outcome of T-cell activation. Our finding is of potential importance for the development of new therapeutics that will be designed to enhance anti-tumor immunity, or to increase CTLA-4 surface expression in the control of autoimmune disease (i.e. type I diabetes, rheumatoid arthritis).</gtr:exploitationPathways><gtr:id>1668FCB8-8AD6-4221-8B9E-8A7B4BF5BDCB</gtr:id><gtr:outcomeId>r-1532820911.6429286779e2e94</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E3661FE4-8B77-4FA8-80C8-BD161C3A3E27</gtr:id><gtr:title>CTLA-4 trafficking and surface expression.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15cb4351bb27c33bc61c5489aaf18d68"><gtr:id>15cb4351bb27c33bc61c5489aaf18d68</gtr:id><gtr:otherNames>Valk E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>pm_53cc02ec02efaff9a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B5E47D3-41DA-4BA1-82FF-EB5B0F190724</gtr:id><gtr:title>CD28 and CTLA-4 coreceptor expression and signal transduction.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71f622837e531f1f7cfc6205d4887393"><gtr:id>71f622837e531f1f7cfc6205d4887393</gtr:id><gtr:otherNames>Rudd CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>pm_53cc031c031b545f0</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E015395/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>